Restenosis News and Research RSS Feed - Restenosis News and Research

Restenosis means the reoccurrence of stenosis, a narrowing of a blood vessel, leading to restricted blood flow. Restenosis usually pertains to an artery or other large blood vessel that has become narrowed, received treatment to clear the blockage and subsequently become renarrowed. This is usually restenosis of an artery, or other blood vessel, or possibly a vessel within an organ.
Leader of materials technology development at Lucideon publishes third book on medical polymers

Leader of materials technology development at Lucideon publishes third book on medical polymers

Lucideon, the materials technology company, is pleased to announce that its Head of Medical Materials, Dr Xiang Zhang, has recently published his third book, Science and Principles of Biodegradable and Bioresorbable Medical Polymers. [More]
UH cardiologists implant first Abbott Absorb stent on patient with coronary artery disease

UH cardiologists implant first Abbott Absorb stent on patient with coronary artery disease

University Hospitals Case Medical Center is among the first in the country - and the first in Ohio - to offer and deploy the Abbott Absorb stent, a completely bioresorbable stent. [More]
UH implants Abbott's Absorb dissolving stent on coronary artery disease patient

UH implants Abbott's Absorb dissolving stent on coronary artery disease patient

University Hospitals Case Medical Center is among the first in the country - and the first in Ohio - to offer and deploy the Abbott Absorb stent, a completely bioresorbable stent. The Absorb stent works exactly as its traditional metallic predecessors in that it opens a blocked coronary artery, with one major exception - it dissolves completely in the body two to three years after implantation. [More]
Loyola among first health systems to offer absorbable stent to heart patients

Loyola among first health systems to offer absorbable stent to heart patients

Loyola Medicine will be among the first health systems in the country to offer heart patients a new stent that is absorbed by the body once it has served its purpose. [More]
FDA approves Absorb GT1 BVS to treat coronary artery disease

FDA approves Absorb GT1 BVS to treat coronary artery disease

The U.S. Food and Drug Administration today approved the first fully absorbable stent to treat coronary artery disease. [More]
Everolimus-eluting bioresorbable vascular scaffold shows promise in PAD

Everolimus-eluting bioresorbable vascular scaffold shows promise in PAD

A first-in-human trial of an everolimus-eluting bioresorbable vascular scaffold has shown that the device can achieve a high 2-year patency rate and low 2-year target lesion revascularisation rate in patients with peripheral artery disease involving the external iliac artery and superficial femoral artery. [More]
PCI with polymer-free BA9 drug-coated stent better than bare metal stent in ACS patients

PCI with polymer-free BA9 drug-coated stent better than bare metal stent in ACS patients

Patients with acute coronary syndromes (ACS) who are at high risk for bleeding have significantly lower rates of target lesion revascularisation and fewer adverse events after undergoing percutaneous coronary intervention (PCI) with a polymer-free biolimus-A (BA9) drug-coated stent than with those receiving a bare metal stent (BMS) in results from a sub-study of the LEADERS FREE trial reported for the first time in a late-breaker session at EuroPCR 2016. [More]
Ariste Medical develops drug-eluting mesh for more effective open hernia repair

Ariste Medical develops drug-eluting mesh for more effective open hernia repair

Ariste Medical has revealed new research outlining the company’s novel method for addressing medical device failure in open ventral hernia repair. [More]
Stenting and surgery equally effective at lowering long-term risk of stroke

Stenting and surgery equally effective at lowering long-term risk of stroke

Investigators for the Carotid Revascularization Endarterectomy versus Stenting Trial found that stenting and surgery are equally effective at lowering the long-term risk of stroke from a narrowed carotid artery, according to a study published today in The New England Journal of Medicine. [More]
CREST, ARUBA give long-term updates

CREST, ARUBA give long-term updates

Today's late-breaking trials session at the International Stroke Conference featured the long-term results of CREST and ARUBA, both of which support the original trial findings. [More]
Benefit of using antibody-coated drug-eluting stents for CHD still unclear, shows report

Benefit of using antibody-coated drug-eluting stents for CHD still unclear, shows report

In patients with coronary heart disease requiring a stent implantation, the benefit of treatment with antibody-coated drug-eluting stents (ABC-DES) versus drug-eluting stents without antibody coating (DES) is still unclear. [More]

Medinol introduces NIRxcell CoCr Stent System to coronary marketplace

During the recent 2015 Transcatheter Cardiovascular Therapeutics Meeting held in San Francisco, CA, Medinol Ltd. continued to introduce novel stent solutions to the coronary marketplace. During a satellite symposium, "The BioNIR eDES: The Role of Uniformity in Stent Design to Minimize Restenosis", a renowned physician panel discussed the key attributes of the currently available Medinol NIRxcell CoCr Coronary Stent System and the Medinol eDES Coronary Stent System (in trials, not FDA/CE Mark approved). [More]

Review of haemodynamics in stent development shows spiral flow may be key to improving peripheral arterial stent performance

Vascular Flow Technologies, the medical device company using proprietary Spiral Laminar Flow (SLF™) technology to replicate natural blood flow for enhanced patient outcomes, today announces that 'Haemodynamics and Flow Modification Stents for Peripheral Arterial Disease: A Review’, co-authored by VFT’s non-executive Medical Director Graeme Houston, has been published in the Annals of Biomedical Engineering. The paper reviews the importance of haemodynamics in stent development as a method of improving patency and longevity of the stent. [More]

Medinol announces completion of enrollment in BIONICS trial to evaluate effectiveness of eDES

Medinol, a developer of Interventional Cardiology devices, announced today the completion of enrollment in its BIONICS trial, a global, prospective, randomized, multicenter, clinical trial designed to evaluate the safety and effectiveness of a new Coronary Stent System, the first ever elastomeric Drug Eluting Stent or eDES. [More]
STEMI study: Absorbable stents perform similarly to metallic stents

STEMI study: Absorbable stents perform similarly to metallic stents

A drug-eluting coronary stent made of absorbable material performed similarly to the gold-standard metal one in a non-inferiority trial among patients with the more serious type of heart attack known as ST-segment elevation myocardial infarction (STEMI), according to results of the ABSORB STEMI TROFI II trial. [More]
Clinical trial results of drug-eluting stent for peripheral arterial disease presented at LINC 2015

Clinical trial results of drug-eluting stent for peripheral arterial disease presented at LINC 2015

Historic five-year results from the world’s largest clinical trial of a drug-eluting stent for treating peripheral arterial disease (PAD) were presented last week at the Leipzig Interventional Course, in Germany. The data confirm long-term patency for patients treated with Zilver® PTX®. [More]
Magnus Life Science commemorates unique partnership with UCL to advance bio-medical research

Magnus Life Science commemorates unique partnership with UCL to advance bio-medical research

Magnus Life Science is today celebrating its unique collaboration with University College London (UCL), one of the world's leading universities, to advance bio-medical research and bring real innovation to areas of high unmet medical need. [More]
EMA recommends orphan designation to Magnus Growth's novel therapy for placental insufficiency

EMA recommends orphan designation to Magnus Growth's novel therapy for placental insufficiency

Magnus Life Science today announces that the European Medicines Agency's Committee for Orphan Medicinal Products has reached a positive decision on recommending orphan designation to Magnus Growth's novel therapy to treat placental insufficiency. [More]
Surgical membrane delivers healing action of vitamin A

Surgical membrane delivers healing action of vitamin A

When blood vessels are damaged through surgery, it can trigger an endless cycle of scarring and repair. [More]
New study identifies crizotinib drug as possible new coating for drug-eluting stents

New study identifies crizotinib drug as possible new coating for drug-eluting stents

A new study has identified an FDA approved cancer drug, crizotinib, as a possible new coating for drug-eluting stents. Researchers found that crizotinib in mice helped prevent the narrowing of blood vessels after stenting without affecting the blood vessel lining. [More]
Advertisement
Advertisement